Patient dies after taking developmental anemia drug: Astellas

Share this article:
Japanese drugmaker Astellas and FibroGen reported that a US patient died of liver failure after taking their experimental anemia medicine known as FG-2216. FibroGen, based in San Francisco, reported the fatality to the FDA and will discuss the cause of death and future plans for the drug with the FDA, Astellas said in a statement on its Web site. Both companies are analyzing information on the case, which involved a 76-year-old patient taking 10 other medications, according to Astellas. FG-2216 is in Phase II testing and aims to help patients with chronic kidney disease and cancer increase levels of erythropoietin that stimulates production of red-blood cells. FG-2216 is an oral treatment being developed as an alternative to Amgen’s Epogen and Aranesp and Johnson & Johnson’s Procrit, injectables that have been linked to deadly side effects, including strokes and heart attacks, in patients with chronic kidney failure.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...